|
Market Closed -
Euronext Paris
11:55:00 2026-11-13 EST
|
5-day change | 1st Jan Change | ||
| 28.82 EUR | -0.89% |
|
+1.34% | +14.37% |
| 11-03 | Uzedy annual sales targets raised, Medincell benefits | |
| 10-14 | Medincell bolsters financial structure, Jefferies approves |
| Market Cap | 1.03B 1.14B 957M 864M 1.63B 108B 1.69B 11.5B 4.56B 57.52B 4.29B 4.2B 183B | P/E 2027 * |
812x | P/E 2028 * | 54.4x |
|---|---|---|---|---|---|
| Enterprise Value | 1.01B 1.11B 933M 842M 1.59B 105B 1.64B 11.21B 4.44B 56.07B 4.18B 4.09B 178B | EV / Sales 2027 * |
25.9x | EV / Sales 2028 * | 17.4x |
| Free-Float |
66.07% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| MEDCL | Real-time | |
| 0ACH | Delayed | ||
| Real-time | |||
| MEB | Delayed | ||
| MDCLF | Delayed | ||
| MEB | Real-time | ||
| MEB | Delayed | ||
| 0ACH | Real-time | ||
| MEB | Real-time |
Last Transcript: MedinCell S.A.
| 1 day | -0.89% | ||
| 1 week | +1.34% | ||
| Current month | +9.33% | ||
| 1 month | +9.50% | ||
| 3 months | +19.59% | ||
| 6 months | +5.26% | ||
| Current year | +14.37% |
| 1 week | 28.4 | 30.68 | |
| 1 month | 25.04 | 30.68 | |
| Current year | 19.69 | 32.38 | |
| 1 year | 19.69 | 32.38 | |
| 3 years | 5.92 | 39.68 | |
| 5 years | 4.73 | 39.68 | |
| 10 years | 4.35 | 39.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Christophe Douat
CEO | Chief Executive Officer | 62 | 2003-01-08 |
Stéphane Postic
DFI | Director of Finance/CFO | 52 | 2023-08-31 |
Philippe Moyen
COO | Chief Operating Officer | - | 2024-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Christophe Douat
BRD | Director/Board Member | 62 | 2003-01-08 |
Philippe Guy
CHM | Chairman | - | 2024-03-12 |
Elisabeth Kogan
BRD | Director/Board Member | - | 2020-12-14 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/21/26 | Buy | Chief Executive Officer | 70,000 | 0.1948% | ||
| 2/26/25 | Buy | General Counsel | 2,943 | 0.0099% | ||
| 2/21/25 | Buy | Chief Financial Officer | 3,749 | 0.0126% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.89% | +1.34% | -5.32% | +372.46% | 1.14B | ||
| +1.26% | +6.61% | +40.79% | +145.27% | 1,286B | ||
| +0.79% | +3.45% | +45.84% | +92.04% | 688B | ||
| +0.20% | +1.28% | +26.97% | +114.41% | 521B | ||
| -0.44% | +3.69% | +41.45% | +70.04% | 386B | ||
| +0.55% | +0.70% | +59.02% | +45.79% | 364B | ||
| -0.12% | +0.74% | +28.39% | +60.32% | 302B | ||
| +0.37% | +0.37% | +3.33% | +38.57% | 287B | ||
| -0.30% | +1.14% | +38.29% | +70.56% | 252B | ||
| +0.08% | +0.71% | +34.44% | +123.99% | 208B | ||
| Average | +0.15% | +2.00% | +31.32% | +113.34% | 430B | |
| Weighted average by Cap. | +0.54% | +3.26% | +37.69% | +99.36% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 38.94M 42.97M 36.02M 32.5M 61.24M 4.05B 63.4M 433M 172M 2.16B 161M 158M 6.87B | 56.6M 62.46M 52.35M 47.24M 89.02M 5.89B 92.15M 629M 249M 3.15B 234M 229M 9.99B |
| Net income | -2.73M -3.02M -2.53M -2.28M -4.3M -284M -4.45M -30.37M -12.04M -152M -11.32M -11.08M -482M | 20.09M 22.17M 18.58M 16.77M 31.6M 2.09B 32.71M 223M 88.52M 1.12B 83.21M 81.44M 3.54B |
| Net Debt | -26.23M -28.95M -24.26M -21.89M -41.26M -2.73B -42.71M -291M -116M -1.46B -109M -106M -4.63B | -49.43M -54.55M -45.72M -41.25M -77.74M -5.14B -80.48M -549M -218M -2.75B -205M -200M -8.72B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-13 | €28.82 | -0.89% | 31,547 |
| 26-11-12 | €29.08 | -2.48% | 63,297 |
| 26-11-11 | €29.82 | +0.20% | 50,750 |
| 26-11-10 | €29.76 | -0.80% | 117,587 |
| 26-11-09 | €30.00 | +5.49% | 178,878 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- MEDCL Stock
Select your edition
All financial news and data tailored to specific country editions
















